Achieving Over 30% Body Weight Loss With Semaglutide in a Patient: A Case Report

Area of Science:

• Endocrinology
• Metabolic Disorders
• Pharmacology

Background:

• Morbid obesity (BMI ≥ 40) is a complex metabolic condition associated with significant health risks, including hypertension and hyperglycemia.
• Effective and safe weight management strategies are crucial for improving patient outcomes and reducing comorbidities.
• Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a promising therapeutic agent for weight reduction.

Observation:

• A 69-year-old female patient with morbid obesity (BMI: 47) and pre-existing hypertension was treated with semaglutide.
• The patient's initial weight was 241 lb.
• Treatment duration was 65 weeks.

Findings:

• The patient achieved a significant weight loss of 90 lb, representing over 30% of her total body weight.
• This weight reduction surpassed the average outcomes reported in previous clinical studies on semaglutide for weight management.
• The patient experienced no adverse side effects during the treatment period.
• Concurrently, her hypertension resolved, and her blood glucose levels normalized.

Implications:

• Semaglutide demonstrates potent efficacy in inducing substantial and sustained weight loss in individuals with morbid obesity.
• The drug offers multifaceted health benefits beyond weight reduction, including the resolution of comorbidities like hypertension and normalization of glycemic control.
• These findings support the role of semaglutide as a valuable therapeutic option for managing obesity and its associated metabolic disturbances.